Research Areas

Research Areas

The 2020 AMR Benchmark compares what 30 pharmaceutical companies are doing to help bring antimicrobial resistance under control. Its 2020 assessment is based on a framework of 19 metrics across three Research Areas. Here are summaries of the 2020 Benchmark's findings from each Research Area, including which companies take the lead.     

Research & Development

Read what the 2020 AMR Benchmark found when it analysed the R&D pipelines of eight large research-based companies and 13 pharmaceutical SMEs. It has mapped their medicine and vaccine projects targeting priority bacterial and fungal pathogens.

Read the results

Responsible Manufacturing

Read the results of the 2020 AMR Benchmark analysis into how eight large research-based companies and nine generic medicine manufacturers aim to minimise the risk that antibacterial discharge released from factories contributes to AMR.

Read the results

Appropriate Access & Stewardship

Read the findings from the 2020 AMR Benchmark on access strategies for antibacterial and antifungal products in LMICs from eight large research-based companies and nine generic medicine manufacturers, as well as stewardship initiatives.

Read the results

Back to top |